Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
Michael R. Bogart, PharmD
Advertisement
Articles by Michael R. Bogart, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
4
Melatonin Use Linked to Small REM Sleep Reduction in Children
5